Maud Eijkenboom

Maud Eijkenboom has a wealth of experience in various roles within the pharmaceutical and biotechnology sectors. Currently serving as the Managing Director at LIXA, Maud focuses on providing scalable antimicrobial resistance solutions. Maud also holds the title of Director at West Australian Pharmaceuticals, where Maud oversees consultancy services for biotechnology and pharmaceutical commercialization. With a background in Neurobiology, Neurosciences, and Psychology, Maud has a strong foundation for their work in research, development, and commercialization within the life science sector.